## Soledad Retamozo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7216995/publications.pdf

Version: 2024-02-01

46 papers

1,416 citations

471509 17 h-index 31 g-index

47 all docs

47 docs citations

47 times ranked

1813 citing authors

#	Article	IF	CITATIONS
1	Crioglobulinemia. Medicina ClÃnica, 2022, 158, 478-487.	0.6	5
2	Characterization and outcomes of 414 patients with primary SS who developed haematological malignancies. Rheumatology, 2022, 62, 243-255.	1.9	12
3	Haemophagocytic syndrome and COVID-19. Clinical Rheumatology, 2021, 40, 1233-1244.	2.2	53
4	Therapeutic Recommendations for the Management of Older Adult Patients with Sjögren's Syndrome. Drugs and Aging, 2021, 38, 265-284.	2.7	4
5	An update of targeted therapeutic options for primary Sjögren syndrome: current status and future development. Expert Opinion on Pharmacotherapy, 2021, 22, 2359-2371.	1.8	6
6	SARS-CoV-2 infection in patients with systemic autoimmune diseases. Clinical and Experimental Rheumatology, 2021, 39, 676-687.	0.8	8
7	Post-COVID-19 syndrome in patients with primary Sj $\tilde{A}$ gren's syndrome after acute SARS-CoV-2 infection. Clinical and Experimental Rheumatology, 2021, , .	0.8	O
8	Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium. Clinical and Experimental Rheumatology, 2021, 39, 166-174.	0.8	12
9	Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium Clinical and Experimental Rheumatology, 2021, 39 Suppl 133, 166-174.	0.8	O
10	SARS-CoV-2 infection in patients with systemic autoimmune diseases. Clinical and Experimental Rheumatology, 2021, 39, 676-687.	0.8	20
11	EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies. Annals of the Rheumatic Diseases, 2020, 79, 3-18.	0.9	307
12	Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sjögren's syndrome. RMD Open, 2019, 5, e001064.	3.8	53
13	Prognostic markers of lymphoma development in primary Sjögren syndrome. Lupus, 2019, 28, 923-936.	1.6	51
14	Clinically-useful serum biomarkers for diagnosis and prognosis of sarcoidosis. Expert Review of Clinical Immunology, 2019, 15, 391-405.	3.0	70
15	SAT0385â€Multiple infection is independently related to death in adult patients with hemophagocytic syndrome: etiopathogenically-driven multivariate analysis in 151 patients., 2018,,.		O
16	THU0665â€Pharmacovigilance surveillance of autoimmune diseases induced by biological agents: a review of 16123 cases (AEBIOGEAS-SEMI REGISTRY). , 2018, , .		0
17	AB1266â€Autoimmune diseases induced by biological agents used in patients with advanced cancer: a nationwide multicenter registry of cases diagnosed in daily practice (CBIOGEAS-SEMI). , 2018, , .		O
18	SAT0416â€Life-threatening primary sj×gren syndrome: clinical characterisation and outcomes in 1535 patients (GEAS-SS REGISTRY). , 2018, , .		0

#	Article	IF	Citations
19	Severe, life-threatening phenotype of primary SjĶgren's syndrome: clinical characterisation and outcomes in 1580 patients (GEAS-SS Registry). Clinical and Experimental Rheumatology, 2018, 36 Suppl 112, 121-129.	0.8	21
20	Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry). Expert Opinion on Drug Safety, 2017, 16, 1255-1271.	2.4	106
21	Diagnosis of Liver Involvement in Primary Sjögren Syndrome. Journal of Clinical and Translational Hepatology, 2016, 1, 94-102.	1.4	19
22	Cryoglobulinaemic vasculitis at diagnosis predicts mortality in primary Sjögren syndrome: analysis of 515 patients. Rheumatology, 2016, 55, 1443-1451.	1.9	51
23	Treating the Underlying Pathophysiology of Primary Sjögren Syndrome: Recent Advances and Future Prospects. Drugs, 2016, 76, 1601-1623.	10.9	15
24	Sarcoidosis: an update on current pharmacotherapy options and future directions. Expert Opinion on Pharmacotherapy, 2016, 17, 2431-2448.	1.8	37
25	Systemic activity and mortality in primary Sjögren syndrome: predicting survival using the EULAR-SS Disease Activity Index (ESSDAI) in 1045 patients. Annals of the Rheumatic Diseases, 2016, 75, 348-355.	0.9	149
26	Early diagnosis of primary Sjögren's syndrome: EULAR-SS task force clinical recommendations. Expert Review of Clinical Immunology, 2016, 12, 137-156.	3.0	118
27	THU0408 How we are Treating Our Systemic Patients with Primary Sjögren Syndrome? Analysis of 1120 Patients (GEAS-SS Spanish Registry). Annals of the Rheumatic Diseases, 2015, 74, 344.2-344.	0.9	0
28	Etiopathogenic Role of Surfactant Protein D in the Clinical and Immunological Expression of Primary Sj $\tilde{A}$ ¶gren Syndrome. Journal of Rheumatology, 2015, 42, 111-118.	2.0	12
29	How are we treating our systemic patients with primary Sjögren syndrome? Analysis of 1120 patients. International Immunopharmacology, 2015, 27, 194-199.	3.8	25
30	OP0274â€Cryoglobulinemic Vasculitis and Primary sjögren's Syndrome are Independent Risk Factors for Lymphoma in a Large Worldwide Population of Patients with Positive Serum Cryoglobulins. Annals of the Rheumatic Diseases, 2015, 74, 175.3-176.	0.9	0
31	OP0213â€The Degree of Activity Measured with the EULAR-SS Disease Activity Index (ESSDAI) Strongly Correlated with Death in Patients with Primary Sjogren Syndrome (GEAS-SS REGISTRY). Annals of the Rheumatic Diseases, 2014, 73, 143.1-143.	0.9	1
32	THU0399â€Systemic Amyloidosis as A Multi-Organ, Life-Threatening Disease: Predictive Baseline Factors Associated to Mortality in 570 Patients (Ramyd-Geas-Semi Registry). Annals of the Rheumatic Diseases, 2014, 73, 319.3-320.	0.9	0
33	THU0398â€Adult Hemophagocytic Syndrome: Analysis of 50 Cases (Spanish National Registry Geas-Semi). Annals of the Rheumatic Diseases, 2014, 73, 319.2-319.	0.9	0
34	SATO206â€Minimally-Invasive Technique for the Biopsy of Minor Salivary Glands: Searching for Systemic Infiltrative Diseases in Patients Presenting with SICCA Symptoms. Annals of the Rheumatic Diseases, 2014, 73, 664.2-664.	0.9	1
35	Validation of the classification criteria for cryoglobulinaemic vasculitis. Rheumatology, 2014, 53, 2209-2213.	1.9	67
36	AB0542â€Blocking the Human B Lymphocyte Stimulator Molecule (BLYS) Using A Monoclonal Antibody (Belimumab) in Systemic Lupus Erythematosus: First Results in Real-Life Spanish Patients with Refractory Disease (Biogeas-Semi Registry). Annals of the Rheumatic Diseases, 2014, 73, 985.2-985.	0.9	5

3

#	Article	IF	CITATIONS
37	OP0211â€Association between Systemic Activity and Lymphoma in Primary Sjogren Syndrome: Baseline Essdai Predictors in 921 Spanish Patients (GEAS-SS Registry). Annals of the Rheumatic Diseases, 2014, 73, 142.2-142.	0.9	3
38	THU0298â€Are Anti-La Antibodies A Potential Protection for Hepatitis C Virus Infection in Sj×Gren Syndrome? Analysis in 663 Patients. Annals of the Rheumatic Diseases, 2014, 73, 286.2-286.	0.9	0
39	THU0397â€Clinical Presentation and Characterization of Neurosarcoidosis: Analysis in 719 Patients (Sarcogeas-Semi Registry). Annals of the Rheumatic Diseases, 2014, 73, 319.1-319.	0.9	O
40	THU0396â€lgg4-Related Disease or Primary Sjogren Syndrome? Organ-Specific Involvement and Immunological Profile Are Clues in Differentiating Two Diseases with A Common Clinical Presentation. Annals of the Rheumatic Diseases, 2014, 73, 318.3-319.	0.9	0
41	AB1089â€Diagnosis of Systemic Inflammatory Diseases in Patients with Fever Referred to A Quick Diagnosis Unit: Experience of A Third Level Teaching Hospital in Barcelona. Annals of the Rheumatic Diseases, 2014, 73, 1161.3-1162.	0.9	O
42	SAT0175â€Results of the Classification Criteria for Cryoglobulinemic Vasculitis Validation Study. Annals of the Rheumatic Diseases, 2013, 72, A640.2-A641.	0.9	0
43	Life-Threatening Cryoglobulinemic Patients With Hepatitis C. Medicine (United States), 2013, 92, 273-284.	1.0	69
44	Cryoglobulinemic disease. Oncology, 2013, 27, 1098-1105, 1110-6.	0.5	15
45	Monoclonal gammopathy related to Sj $\tilde{A}^{f q}$ gren syndrome: A key marker of disease prognosis and outcomes. Journal of Autoimmunity, 2012, 39, 43-48.	6.5	70
46	Anti-Ro52 antibody testing influences the classification and clinical characterisation of primary Sj $ ilde{A}$ ¶gren's syndrome. Clinical and Experimental Rheumatology, 2012, 30, 686-92.	0.8	28